Jo, Helen E., Glaspole, Ian, Macansh, Sacha, Grainge, Christopher, Keir, Gregory J., Hayen, Andrew, Henderson, Douglas, Klebe, Sonja, Heinze, Stefan B., Miller, Anne, Rouse, Hannah C., Duhig, Edwina, Goh, Nicole, Cooper, Wendy A., Mahar, AM, Ellis, S, McCormack, SR, Ng, B, Godbolt, DB, Corte, TJ, Hopkins, Peter M. A., Moodley, Yuben, Reynolds, Paul N., Chapman, Sally, Walters, Eugene Haydn, Zappala, Christopher, Allan, Heather. John Wiley & Sons; 2019. Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Jo, Helen E., Corte, Tamera J., Allan, Heather, Keir, Gregory J., Cooper, Wendy A., Mahar, Annabelle M., Ellis, Samantha, Macansh, Sacha, Goh, Nicole S., Glaspole, Ian, Grainge, Christopher, Hopkins, Peter M. A., Moodley, Yuben, Reynolds, Paul N., Chapman, Sally, Walters, E. Haydn, Zappala, Christopher. Biomed Central (BMC); 2019. Gastroesophageal reflux and antacid therapy in IPF: Analysis from the Australia IPF Registry.

Burgess, Andrew, Goon, Ken, Brannan, John D., Attia, John, Palazzi, Kerrin, Oldmeadow, Christopher, Corte, Tamera J., Glaspole, Ian, Goh, Nicole, Keir, Gregory, Allan, Heather, Chapman, Sally, Cooper, Wendy, Ellis, Samantha, Hopkins, Peter, Moodley, Yuben, Reynolds, Paul, Zappala, Chris, Macansh, Sacha, Grainge, Cristopher. Wiley-Blackwell; 2019. Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing.